Neurocognitive Disorders - Dementia Flashcards
dementia
cognitive DECLINE (AQUIRED deficit, not developmental)
- more than one cognitive domain affected
- social/occupational functioning impairment
- static or progressive
All patients w/ Alzheimer’s have _____
All patients w/ Alzheimer’s have DEMENTIA
but NOT all pts w/ dementia have Alzheimer’s.
Neurocognitive Disorders (NCDs), major and minor
include delirium, conditions involving substantial decline in a single cognitive domain, conditions affecting younger individuals (e.g. TBI, HIV) as well as previously described dementias
6 cognitive domains
- complex attention
- executive function
- learning and memory
- language
- perceptual - motor
- social cognition
Major Neurocognitive Disorder due to Alzheimer’s disease (DSM-V)`
- evidence of INSIDIOUS onset, GRADUAL progression of impairment, and significant cognitive DECLINE from a previous level of performance in 2 or more of the 6 cognitive domains, based upon:
- -> Concern of decline expressed by the individual/others
- -> Substantial impairment in cognitive performance (standardized testing, etc) - either evidence of gene mutation OR memory/learning affected domains
- cognitive deficits interfere w/ daily independence
- cognitive deficits do NOT occur exclusively in context of delirium
Mild Neurocognitive Disorder due to Alzheimer’s disease (DSM-V)
The cognitive deficits do NOT interfere with capacity for independence in everyday activities
NCD due to Alzheimer’s is the most common cause of _____ in the elderly.
NCD due to Alzheimer’s is the most common cause of psychosis in the elderly.
MCD due to Alzheimer’s prominent behavioral sx
- depression
- apathy
- irritability
- paranoid
- visual hallucinations
- agitation
- sleep disturbance
- wandering
- combativeness
- misidentification sx (thinks husband is imposter)
Amyloid cascade hypothesis
Amyloid Precursor Protein (APP)
1. cleaved by alpha-secretase to a benign breakdown product in the non-amyloidogenic pathway
OR
2. cleaved by beta-secretase and then gamma-secretase to form beta amyloid/amyloid-beta/A-beta/Αβ –> AGGREGATION and NEUROTOXICITY
Strategies to reduce beta-amyloid
- reduce production, vaccinate, facilitate clearance, prevent aggregation of beta amyloid
recent: use of monoclonal Abs directed against beta amyloid very early in the course of the illness
MCD due to Alzheimer’s unmodifiable risk fx
- Advancing age
- Family history and genetics
- first degree relative affected
- Apolipoprotein E (APOE) genotype
- Rare autosomal dominant “deterministic” genes - Down’s syndrome –> highly increased risk
- Female gender (some disagreement)
- head trauma
- low educational levels
- vascular risk fx (sedentary/obesity/smoking/HTN etc.)
Apolipoprotein E (APOE) genotypes (which increases risk? neutral? protective?)
APOE-4 allele, esp. homozygous –> inc risk (earlier onset, possibly via impaired Beta amyloid clearance)
APOE-3 allele, neutral
APOE-2 allele, may be PROTECTIVE
MCD due to Alzheimer’s biomarkers
- Measures of brain beta-amyloid deposition
- diminished CSF beta-amyloid (not getting cleared)
- positive amyloid in PET imaging - Measures of neurodegeneration
- inc CSF tau (tangles)
- dec glucose uptake in parietal/temporal cortex (FDG PET)
- structural imaging (MRI)
- PET tau imaging
MCD due to Alzheimer’s:
FDA approved meds
Cholinesterase Inhibitors
N-methyl-D-aspartate (NMDA) Partial Receptor Antagonists
- blocks xs glutamate (excitatory)
In elderly pts w/ dementia, how are Behavioral and Psychological Symptoms of Dementia (BPSD) and caregiver burden reduced?
Anticholinergic burden reduction (by reducing or eliminating medications with CNS anticholinergic side effect)